A Liquid crystal creams represent a novel approach in skincare formulations, leveraging the unique properties of liquid crystal technology to improve skin hydration and barrier function. The composition, structure, and skincare benefits of recent developments in liquid crystal cream formulations are highlighted in this article. Liquid crystal creams mimic the lipid bilayers of the skin, offering enhanced compatibility and permeability. Liquid crystal creams have emerged as a promising vehicle for topical drug delivery in pharmaceutical formulations, offering unique advantages for enhancing drug permeation, stability, and efficacy. This comprehensive review explores the application of liquid crystal technology in topical drugdeliverysystems, witha focus on composition, structure, and therapeutic applications. Liquid crystal creams, by mimicking the organization of biological membranes, facilitate the penetration of drugs across the skin barrier, resulting in improved bioavailability and therapeutic outcomes. Their versatile composition allows for the incorporation of à wide range of drugs, including hydrophilic and lipophilic compound, peptides, and proteins, enabling targeted delivery to specific skin layers or underlying tissues. Furthermore, the rheological properties of liquid crystal creams can be tailored to optimize drug release kinetics, providing sustained and controlled drug delivery over extended periods. Additionally, the incorporation of penetration enhancers and other excipients into liquid crystal creams can further enhance drug permeation and tissue targeting, expanding their potential applications in dermatology, cosmeceuticals, and wound healing. This review highlights the potential of liquid crystal creams as versatile and effective platforms for topical drug delivery in pharmaceutical formulations, with opportunities for continued research and development to optimize their performance and clinical utility.

1.      Kelker, H., and Hatz, R., Handbook of Liquid Crystals, Verlag Chemie, Weinheim, Germany,1980.

2.      Prost J. The Physics of Liquid Crystals. Research Gate, (1993).

3.       Mahajan Jyotsna, Lyotropic Liquid Crystalline System For Effective Topical Delivery of Tolnaftate, Asian Journal of Pharmaceutical research and Development.2018;6 (3):75-80

4.      Encyclopedia of Pharmaceutical Technology. Editors: James Swarbrick, James C. Boylan. Volume 20,page no 117

5.      Reinitzer, F., Beitra¨ge zur Kenntnis des Cholesterins, Monatsh. Chem., 9:412–441 (1888).  

6.      Silver, B., ed., The Physical Chemistry of Membranes, Allen & Unwin, Inc., & Solomon Press, Winchester, MA, 1985.

7.      Schuetze, W., and Mueller-Goymann, C.C., Mutual interactions between nonionic surfactants and gelatin—investigations in cubic liquid crystalline systems and micellar systems, Colloid Polym. Sci., 269:85–90 (1992).

8.      Fu ¨hrer, C., Junginger, H., and Friberg, S., Structural studies of ointments. Part 1: X-ray structure studies on the hydrophilic ointment DAB 7, J. Soc. Cosmet. Chem., 29:703–716 (1978).

9.      Euschen, A., Diffusion in flu ¨ssigkristallinen Silastomeren—ein Beitrag zur Kontrolle der Arz neistofffreisetzung durch Diffusion, Ph.D. Thesis, Universita ¨t des Saarlandes, Saarbru ¨cken, Germany, 1986.

10.   Tiemessen, H.L.G.M., Nonionic Surfactant Systems for Transdermal Drug Delivery, Ph.D. Thesis Leiden University, The Netherlands, 1989.

11.   PallaviKawara, Vishal Pande, Liquid Crystals: A Novel Approach Drug Delivery System, JETIR June , 2019, Volume-6,402-410.

12.   Shaikh Zeba, Liquid Crystalline System: A Novel approach for Drug Delivery, Journal of Biomedical and Pharmaceutical Research 4 (1) 2015, 22-32.

13.   Savita Mandan, MaitreyeeChavan, Cubosomes: Future of Therapeutics, International journal of pharmacy and pharmaceutical research, March 2020 Vol.:17, Issue: 4, 60-69.

14.   YogeshvarTyagi, liquid crystal: An approach to different states of Matter, Pharma innovation journal, 2018, 7(5): 540-545.

15.   Kawamoto H. The history of liquid crystal display. Proceedings of the IEEE, 460-99, 2002

16.   V. Viswanatha, C. Rajaramb, S. R. Fathimac, D. BhanuPriyad, Brief Review of Liquid Crystals, International Journal of Trend in Scientific Research and Development (IJTSRD), 2018, Volume-2,956-961.

17.   Acciacca A, Spong BR, Fleisher D, Hornedo NR. Mol. Pharmaceutics, 5: 956-967(2008).

18.   Rebecca J. Carlton, Jacob T. Hunter, Daniel S. Miller, Reza Abbasi, Peter C. Mushenheim, Lie Na Tan, and Nicholas L. Abbott, Chemical and biological sensing using liquid crystals, LiqCryst Rev, 2013; 1(1): 29–51.

19.   L. Abbott. 1, s.l. US National Library of Medicine. 2013; 1:29-51.

20.   P. V. Patel, J. B. Patel, R. D. Dangar, K. S. Patel, K. N. Chauhan,“ Liquid Crystal Drug Delivery

21.   Garry Myers, Kingsport, Tenn. “Drug delivery system utilizing liquid crystal structure” US 5,891,845/ April 6,1999.

22.   Paavola A, Kilpelaine I, YliruusiJ, Rosenberg P. Controlled release of vancomycine from poloxamer 407 gels. Int. J Pharm., 288:235 244(2005).

23.   Seideman, T (1990). The liquid-crystalline blue phases.

24.   Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid based nanocarriers. Drug Discov Today 2013;18(5-6): 290- 7.

25.   Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm 2010; 396(1-2):179-87

26.   Liquid crystals containing cosmetic and pharmaceutical compositions and methods for utilizing such compositions. GheorgeCioca, Lake Grove, James Hayward, Port jeffeson, Manuel

27.   L. Tan, Glen Clove, Morris Hersteinscarsdae, N. Y. walter, Stamford, conn. s.l. US 4,999,348, March 12, 1991.

28.   S. Murgia, S. Bonacchi, A. M. Falchi, S. Lampis, V. Lippolis, V. Meli, M. Monduzzi, L. Prodi, J. Schmidt, Y. Talmon, et al.,Langmuir 2013, 29, 6673 – 6679.

29.   Imran Tadwee, Dr.SadhanaShahi, VivekRamteke, Iftequar Syed, Liquid Crystals Pharmaceutical Application: A Review,IJPRAS, Volume 1, issue2 (2012), 06-11.

30.   Rego, J.A.; Harvey, Jamie A.A.; MacKinnon, Andrew L.; Gatdula, Elysse (January 2010). "Asymmetric synthesis of a highly soluble 'trimeric' analogue of the chiral nematic liquid crystal twist agent Merck S1011". Liquid Crystals37 (1): 37–43. doi:10.1080 /02678290903359291.

31.   Boyd BJ, Whittaker D V, Khoob S, DaveyG. Hexosome formed from glycerate surfactants Formulation as a colloidal carrier for irinotecan.Internationa Journal of Pharmaceutics, 318: 154-162(2006).

32.   Zahra Karami and MehrdadHamidi, Cubosomes: remarkable drug delivery potential, Drug Discovery Today, Volume 5, Number 5, 790-799, May 2016.

33.   Jean-Marie Lehn, Andreas Herrmann Nicolas Giuseppone “Imine Based Liquid Crystals For The Controlled Release Of Bioactive Materials” Patent App. No 20090306196

34.   DemianaI.Nesseem ,Formulationandevaluationofitraconazolevia liquid crystal for topicaldeliverysystem, JournalofPharmaceuticalandBiomedicalAnalysis 26(2001)387–399

35.   Bunma, Napa; Moungjaroen, Jirapan; and Tanguenyongwatana, Prasan (2013) "Development of GarciniaMangostana Extract in Liquid Crystal Cream for Topical Delivery System," The Thai Journal of Pharmaceutical Sciences: Vol. 38: Iss. 0, Article 48.

Jarupinthusophon, S.; Preechataninrat, P.; Anurukvorakun, O. Development of Liquid Crystal Cream Containing Germinated Brown Rice. Appl. Sci. 2022, 12, 11113. https://doi.org/ 10.3390/app122111113